Medical/Pharmaceuticals

Clarity commences Cu-64/Cu-67 SAR-bisPSMA theranostic prostate cancer trial

SYDNEY, July 28, 2021 /PRNewswire/ -- Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has commenced its64/67Cu SAR-bisPSMA theranostic clinical trial in patients with metastatic castrate resistant pr...

2021-07-28 21:08

Leaf Space Applies Satellite Solutions to Enhance Connectivity for Home Monitoring of COVID-19 Patients with CARES Monitoring System

GSaaS solutions company is supported by the European Space Agency to test satellite enabled telemedicine technology to remotely care for recovering COVID-19 patients MILAN, July 28, 2021 /PRNewswire/ -- Leaf Space, a leading provider of ground segment as-a-service (GSaaS) solutions, announced to...

2021-07-28 21:00

Fortacin™ Receives Extremely Encouraging Assessment in US Market Research Analysis

HONG KONG, July 28, 2021 /PRNewswire/ -- Endurance RP Limited ("Endurance Longevity" or the "Company" and together with its subsidiaries, the "Group"; stock code: 0575.HK) is pleased to announce that Fortacin™, a European,Hong Kong andMacau approved treatment for PE receives a detailed market ass...

2021-07-28 20:05

United Imaging Goes "All-in" for Nashville

HOUSTON, July 28, 2021 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, makes its debut at HealthTrust University and its in-person debut at AHRA inNashville over the next two weeks. At both events, the company will focus on several unique ...

2021-07-28 20:00 109

GenScript Announces Notice of Allowance for U.S. Patent Application for SARS-CoV-2 Surrogate Virus Neutralization Kit

PISCATAWAY, N.J., July 28, 2021 /PRNewswire/ -- GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK), a world-leading life sciences research and application service and product provider, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a notice of allowance...

2021-07-28 19:30

I-Mab Announces IND Acceptance for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China

* Efineptakin alfa in combination with pembrolizumab induced 27.8% ORR in metastatic TNBC patients in a phase1b/2 trial in South Korea * Efineptakin alfa in patients with GBM showed a 83.3% survival ratio over one year in a phase 1 trial in the U.S. SHANGHAI and GAITHERSBURG, Md., July 28, 20...

2021-07-28 19:15 297

BIOTRONIK Applauded by Frost & Sullivan for Its Disruptive Implantable Cardiac Monitoring Device, BIOMONITOR IIIm

LONDON, July 28, 2021 /PRNewswire/ -- Based on its recent analysis of the Global market for implantable cardiac monitoring devices,Frost & Sullivan recognizesBIOTRONIK with the 2021 Global Enabling Technology Leadership Award. The company's subcutaneous miniature, injectable electrocardiogram (EC...

2021-07-28 18:00 267

Eccogene Announces Completed First-in-human of ECC0509 in Phase 1a Clinical Trial in Australia

SHANGHAI, July 28, 2021 /PRNewswire/ -- Eccogene, Inc., a clinical stage biopharmaceutical company focused on discovery and development of metabolic and immunologic therapeutics, announced the initiation of a Phase 1a clinical trial evaluating ECC0509, an oral inhibitor of semicarbazide-sensitive...

2021-07-28 17:13 334

CUHK Develops a Novel Faecal Test that can Detect Polyps and Early Colon Cancers with Sensitivity Over 90%

HONG KONG, July 28, 2021 /PRNewswire/ -- The faecal immunochemical test (FIT) is commonly used to screen for colorectal cancer but it has low sensitivity (around 50%) for early cancer detection and fails to detect polyps. The Faculty of Medicine at TheChinese University of Hong Kong (CU Medicine)...

2021-07-28 15:09 431

Kintor Pharmaceutical Announces Dosing of First Batch of Subjects in Phase I Clinical Trial of GT20029 in China

SUZHOU, China, July 28, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that the company has dosed the first batch of subjects in its phase I clinical trial of...

2021-07-28 13:47 863

Venus Medtech Appoints Professor Martin B. Leon as Global Principal Investigator of Its New-Generation RDN System

HANGZHOU, China, July 28, 2021 /PRNewswire/ -- On July 27, 2021, Venus Medtech ( Hangzhou) Inc. ("Venus Medtech") (stock code: 2500.HK), a leading provider of comprehensive interventional heart valve therapy solutions inChina, and its controlling subsidiary Renaly Ltd., announced that Professor...

2021-07-28 11:41 625

India-based MedTel receives investment term sheet from Catalist-listed Metal Component Engineering (MCE, SGX:5DX)

SINGAPORE, July 28, 2021 /PRNewswire/ -- Catalist-listed Metal Component Engineering Limited ("MCE") is pleased to announce that it has, through its subsidiary, Metal Precision Services Pte Ltd, entered into a term sheet to take an equity stake in MedTel Healthcare Private Limited ("MedTel"). MCE...

2021-07-28 11:36 1054

More than Half of Singaporeans Unaware of Link between Viral Hepatitis and Liver Failure: Survey

* New survey demonstrates general apathy among Singaporeans towards liver health, particularly among those aged 25 and below, despite high rates of liver cancer and failure in the country  * Hepatitis B causes 60-70% of total number of liver cancer cases in the country[1]; liver cancer known ...

2021-07-28 11:00 521

Gilead Sciences Announces Launch of Asia Pacific ALL4LIVER Grant 2021

– Biennial Grant Program Supports Community Projects Focused on Improving Education About Liver Health inSingapore and 10 Other Countries and Territories– – Inaugural Cycle of the Grant will Focus on Hepatitis B Awareness Initiatives –  SINGAPORE, July 28, 2021 /PRNewswire/ -- Gilead Sciences, I...

2021-07-28 11:00 816

Ascletis Announces Completion of 149 Patient Enrollment and Positive Interim Results of Phase IIb Chronic Hepatitis B Study in China for its Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab)

* HBsAg reduction was observed in the 1 mg/kg ASC22 once every two weeks plus nucleos(t)ide analogs group with greater HBsAg reduction observed in patients with HBsAg ≤ 500 IU/mL at baseline while no HBsAg reduction was observed for the placebo plus nucleos(t)ide analogs group * Receptor oc...

2021-07-28 08:30 548

Zepp Health Invests $2.4M to Lead neuro42's Series A Round

CUPERTINO and SAN FRANCISCO, Calif., July 27, 2021 /PRNewswire/ -- Zepp Health Corp. (NYSE: ZEPP), and neuro42, Inc. today announced that Zepp Health is investing$2.4 million to lead the $6.5 million Series A funding round for the development of MRI and robotics technology that allows physicians ...

2021-07-28 04:00 2013

Global Dementia Cases Forecasted To Triple By 2050

—New analysis shows a decrease in prevalence due to education countered by increase due to heart health risk factors DENVER, July 27, 2021 /PRNewswire/ -- Positive trends in global education access are expected to decrease dementia prevalence worldwide by 6.2 million cases by the year 2050. Mean...

2021-07-27 22:00 792

Deep Longevity Repurposes a Blood Aging Clock for Saliva Samples

HONG KONG, July 27, 2021 /PRNewswire/ -- Endurance RP Limited's ("Endurance Longevity" or the "Company" and together with its subsidiaries, the "Group"; stock code: 0575.HK) wholly owned subsidiary Deep Longevity, Inc, a leading provider of deep biomarkers of aging and longevity is pleased to ann...

2021-07-27 21:39 2428

I-Mab Announces Preliminary Proposal for Potential Dual Listing on the STAR Market of the Shanghai Stock Exchange

SHANGHAI and GAITHERSBURG, Md., July 27, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that onJuly 27, 2021, the Board of Directors of the Comp...

2021-07-27 20:35 2377

Zhongchao Inc. Builds A Platform for Breast Cancer Tiered Diagnosis and Treatment Improvement To Promote the Equalization of Breast Cancer Diagnosis and Treatment Level

SHANGHAI, July 27, 2021 /PRNewswire/-- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a healthcare services company offering patient management, online healthcare information, professional training and educational services, today announced that for the first half of 2021, around 1...

2021-07-27 20:30 838
12345 ... 530